Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for elotuzumab

  1. Elotuzumab for previously treated multiple myeloma (terminated appraisal) (TA434)

    NICE is unable to make a recommendation about the use in the NHS of elotuzumab for previously treated multiple myeloma. This is because Bristol–Myers Squibb did not provide an evidence submission.

    Technology appraisal guidance
    Published
    22 March 2017

    Sections for TA434

  2. Elotuzumab for untreated multiple myeloma [ID966]

    Discontinued Reference number: GID-TA10134

    Technology appraisal guidance
    Discontinued

  3. Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467

    Discontinued Reference number: GID-TA10353

    Technology appraisal guidance
    Discontinued